Vivera Pharmaceuticals Issues Statement Regarding LuSys Labo

NEWPORT BEACH, Calif., Jan. 14, 2022 /PRNewswire/ -- Vivera Pharmaceuticals is highly discouraged to read the latest FDA safety communication that...

Related Keywords

United States , White House , District Of Columbia , Megan Kay , Paul Edalat , Peter Navarro , Vivera Pharmaceuticals , Vivera Pharmaceuticals Inc , Access Bio Vivera Pharmaceuticals , Prnewswire Vivera Pharmaceuticals , Lusys Laboratories , Lusys Eagle Diagnostics , Emergency Use Authorized , Use Authorized , Access Bio ,